Core Viewpoint - The pharmaceutical sector experienced a strong rally on the 15th, with notable stocks such as Sunflower reaching a 20% limit up, and Guangsheng Tang and Shutaishen seeing increases of over 17% and nearly 12% respectively [1] Market Performance - Following the National Day holiday, the market continued its pre-holiday trend, primarily driven by technology stocks, while the pharmaceutical sector faced some capital outflow and exhibited relatively volatile performance [1] - Short-term adjustments in the pharmaceutical sector are attributed to profit-taking by investors and limited catalysts, alongside heightened risk aversion due to escalating China-U.S. trade tensions [1] Investment Recommendations - Despite the short-term volatility, the main logic of the innovation trend remains intact, with ongoing developments in new target research, clinical data releases, and cross-border business development [1] - It is recommended to selectively increase positions in high-quality stocks that have key data readout catalysts, potential significant business development transactions, and global growth potential [1] - In light of the long-term complexities of China-U.S. relations, it is advisable to actively select domestic demand sectors with low valuation levels, good chip structures, and stable fundamental recovery for appropriate allocation [1]

10月15日消息，截止10:45，原料药板块强势，亚太药业涨停，向日葵、海辰药业、博腾股份、华海药 业、金达威等个股涨幅居前。 责任编辑：小浪快报 ...

Market Overview - The Shanghai Composite Index is at 3878.54 points, below the five-day moving average, with a change of 0.34% [1] - The total trading volume of A-shares is 946.108 billion yuan [1] Stocks Performance - A total of 854 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Xiangrikui (向日葵) with a deviation rate of 12.17% and a daily increase of 19.97% [1] - Heshun Electric (和顺电气) with a deviation rate of 10.53% and a daily increase of 13.57% [1] - Guangzi International (广咨国际) with a deviation rate of 8.38% and a daily increase of 12.14% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Fute Technology (富特科技) with a deviation rate of 7.46% and a daily increase of 9.54% [1] - Xiangjiang Holdings (香江控股) with a deviation rate of 7.31% and a daily increase of 10.10% [1] - Anglikang (昂利康) with a deviation rate of 7.07% and a daily increase of 10.01% [1] Summary of Key Stocks - The following stocks have shown significant trading activity: - Jiuchisoft (久其软件) with a daily increase of 10.03% [1] - Yuanda Intelligent (远大智能) with a daily increase of 9.97% [1] - Anner (安奈儿) with a daily increase of 7.30% [1]

（文章来源：证券日报） 证券日报网讯 10月13日晚间，向日葵发布公告称，公司子公司浙江贝得药业有限公司于近日取得浙江 省药品监督管理局换发的《药品生产许可证》，同意《药品生产许可证》生产范围的变更。 ...

证券代码：300111 证券简称：向日葵 公告编号：2025—046 浙江向日葵大健康科技股份有限公司 关于子公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）子公司浙江贝得 药业有限公司于近日取得浙江省药品监督管理局换发的《药品生产许可证》，同 意《药品生产许可证》生产范围的变更，具体登记变更事项如下： 一、变更内容 社会信用代码：91330600765236277X 法定代表人：唐小波 企业负责人：杨自英 质量负责人：章瑾 有效期至：2030 年 8 月 11 日 许可证编号：浙 20050286 1、自产生产范围的修改：增加药品 GMP 符合性检查编号、药品 GMP 符合 性检查范围。 2、受托生产范围的修改：委托方广东稳健药业有限公司的受托产品多巴丝 肼片，受托信息中修改了委托方注册地址及产品规格描述；增加了药品 GMP 符 合性检查编号、药品 GMP 符合性检查范围、药品批准文号及批准文号有效期。 二、《药品生产许可证》的基本信息 企业名称：浙江贝得药业有限公司 注册地址 ...

New Stock Listings - New stock "Aomeisen" (920080) listed at an issue price of 8.25 on October 10, 2025[1] - "Shangwei New Materials" (688585) has a tender offer period from September 29 to October 28, 2025[1] Delisting and Trading Alerts - "Zitian Tui" (300280) is in the delisting arrangement period with only 1 trading day remaining[1] - "Pinming Technology" (688109) is experiencing severe abnormal fluctuations[1] Market Updates - Multiple companies including "Kesi Technology" (688788) and "Bory Medical" (688166) have recent announcements related to trading activities[1] - "Ganfeng Lithium" (002460) and "Luoyang Molybdenum" (603993) have also made recent disclosures[1] Additional Information - A total of 30 companies have been highlighted for various trading activities and announcements on October 10, 2025[1] - Links to detailed announcements for each company are provided for further insights[1]

证券日报网讯向日葵10月9日在互动平台回答投资者提问时表示，公司披露的预案内容真实、准确、完 整，公司严格按照监管相关规定履行信息披露义务。 （文章来源：证券日报） ...

证券日报网讯向日葵10月9日在互动平台回答投资者提问时表示，公司密切关注市场环境及政策导向变 化，经营未受关税影响。 （文章来源：证券日报） ...

四川峨眉山：向日葵绽放迎客来【3】 四川峨眉山：向日葵绽放迎客来【4】 四川峨眉山：向日葵绽放迎客来 四川峨眉山：向日葵绽放迎客来【2】 ...

Market Overview - The Shanghai Composite Index rose by 0.52% on September 30, with 19 out of 28 sectors experiencing gains, led by the non-ferrous metals and defense industries, which increased by 3.22% and 2.59% respectively [1] - The pharmaceutical and biological industry saw an increase of 1.40% [1] - The sectors with the largest declines were telecommunications and non-bank financials, which fell by 1.83% and 1.14% respectively [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 32.303 billion yuan, with only four sectors seeing net inflows [1] - The defense industry had the highest net inflow of 2.059 billion yuan, while the non-ferrous metals sector followed with a net inflow of 1.984 billion yuan [1] - The non-bank financial sector experienced the largest net outflow, totaling 11.405 billion yuan, followed by telecommunications with a net outflow of 5.936 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector had a net inflow of 984 million yuan, with 310 out of 475 stocks rising, including two hitting the daily limit [2] - The top three stocks by net inflow were WuXi AppTec with 1.113 billion yuan, followed by Hengrui Medicine and Yong'an Pharmaceutical with 431 million yuan and 134 million yuan respectively [2] - Nine stocks in this sector saw net outflows exceeding 50 million yuan, with C Jianfa Zhi leading at 896.727 million yuan [3] Top Gainers in Pharmaceutical Sector - WuXi AppTec increased by 6.42% with a turnover rate of 2.86% and a main capital flow of 1.112 billion yuan [2] - Hengrui Medicine rose by 3.40% with a turnover rate of 0.91% and a main capital flow of 431 million yuan [2] - Yong'an Pharmaceutical saw a rise of 6.92% with a turnover rate of 16.56% and a main capital flow of 134 million yuan [2] Top Losers in Pharmaceutical Sector - C Jianfa Zhi decreased by 15.04% with a turnover rate of 52.49% and a main capital flow of -896.727 million yuan [3] - Xiangrikui rose by 2.00% but had a net outflow of 854.806 million yuan [3] - Jilin Aodong fell by 1.91% with a net outflow of 797.945 million yuan [3]